

June 2024 Pharmacy & Therapeutics Committee Decisions

Aspirus' Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to review and make changes to the Aspirus Medicare Formulary (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for Medicare formularies are tentative until Aspirus receives final CMS approval.

Key

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

NEW DRUG REVIEW			
DRUG	INDICATION	FORMULARY COVERAGE	EFFECTIVE DATE
Bimzelx (bimekizumab)	Moderate to severe plaque psoriasis (PsO) in adults who are candidates for systemic therapy or phototherapy.	Non-Formulary	N/A
Truqap (capivasertib) PROTECTED CLASS DRUG	for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer (mBC) with ≥ 1 PIK3CA/AKT1/PTEN-alteration as detected by an FDA-approved test, following progression on ≥ 1 endocrine-based regimen in mBC or recurrence on or within 12 months of completing adjuvant therapy, in combination with fulvestrant.	Formulary	08/01/2024
Augtyro (repotrectinib) PROTECTED CLASS DRUG	Treatment of adult patients with locally advanced or metastatic ROS1-positive non small cell lung cancer (NSCLC)	Formulary	08/01/2024
Fruzaqla (fruquintinib) PROTECTED CLASS DRUG	Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) therapy, and, if rat sarcoma virus (RAS) wild-type and medically appropriate, an anti-epidermal growth factor receptor (EGFR) therapy	Formulary	08/01/2024

June 2024 Pharmacy & Therapeutics Committee Decisions

Ojjaara (mometotinib) PROTECTED CLASS DRUG	Treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF (post-polycythemia vera [PV] and post-essential thrombocythemia [ET]), in adults with anemia	Formulary	08/01/2024
---	--	-----------	------------

Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 8/1/2024.

NEW INDICATIONS REVIEW		
DRUG	CURRENT FORMULARY STATUS	RECOMMENDATION
Fanapt (iloperidone) 1, 2, 4, 6, 8, 10, & 12 mg tablets for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults	Formulary	No change
Dovato (dolutegravir and lamivudine) 50 mg-300 mg tablet for HIV-1 in patients ≥ 12 age expansion regimen for complete HIV-1 expanded indication	Formulary	No change
Vemlidy (tenofovir alafenamide) 25 mg tablet for hepatitis B in patients ≥ 6 age expansion	Formulary	No change
Nexletol (bempedoic acid) 180 mg tablets and Nexlizet (bempedoic acid and ezetimibe) 180 mg-10 mg tablets for primary & secondary prevention of MI and coronary revascularization in adults	Non-Formulary	No change
Ixinity (coagulation factor IX, recombinant) 250, 500, 1000, 1500, 2000, & 3000 IU vials for hemophilia B age expansion	Formulary	No change
Enhertu (fam-trastuzumab deruxtecan) 100 mg for IV infusion for unresectable or metastatic HER2-positive (IHC 3+) solid tumors	Non-Formulary	No change
Tivdak (tisotumab vedotin) 40 mg vial for IV infusion for recurrent or metastatic	Non-Formulary	No change

June 2024 Pharmacy & Therapeutics Committee Decisions

cervical cancer full approval		
Ultomiris (ravulizumab) 100 mg/mL vials for IV infusion for neuromyelitis optica spectrum disorder (NMOSD)	Non-Formulary	No change

NEW GENERICS REVIEW		
DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
Adalimumab-aaty (unbranded Yuflyma) 20 mg/0.2 mL prefilled syringe kit and 40 mg/0.4 mL, & 80 mg/0.8 mL autoinjector kits for various inflammatory conditions	An unbranded version of Yuflyma, adalimumab-aaty, has recently launched with WAC price just over \$1000, similar to most of the other low-WAC adalimumab biosimilars.	Non-Formulary
Adalimumab-adbm & -ryvk (unbranded Cyltezo & unbranded Simlandi) 40 mg/0.8 mL & 40 mg/0.4 mL injections for various inflammatory conditions	Unbranded adalimumab biosimilars to Cyltezo and Simlandi are launching.	Non-Formulary
Estrogel (estradiol) 0.06% gel for vasomotor symptoms & vulvar/vaginal symptoms due to menopause	Estrogel (estradiol 0.06%) gel recently had a generic launch.	Non-Formulary
Myrbetriq (mirabegron) ER 25 mg & 50 mg tablets for overactive bladder (OAB)	Two manufacturers (Zydus and Lupin) recently launched generic mirabegron 25 & 50 mg ER tablets. There is ongoing litigation related to this generic launch, however the generic tablets are currently available at ~14% lower cost than the brand product	Non-Formulary
Tyenne (tocilizumab) and Tofidence (tocilizumab) 20mg/mL vials for IV infusion for arthritis (Actemra biosimilars)	Two biosimilar products for Actemra have launched – Tyenne and Tofidence. These are biosimilars to the IV formulation only	Non-Formulary

June 2024 Pharmacy & Therapeutics Committee Decisions

ADDITIONAL ITEMS REVIEWED	
ITEM	DRUGS WITH NEW POLICIES
New Medical Drug Policies (effective 08/01/2024)	<ul style="list-style-type: none">• Anktiva• Beqvez• Lenmeldy